167 related articles for article (PubMed ID: 35287613)
1. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
[TBL] [Abstract][Full Text] [Related]
2. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
3. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
[TBL] [Abstract][Full Text] [Related]
4. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
[TBL] [Abstract][Full Text] [Related]
5. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Yardley DA; Hart L; Bosserman L; Salleh MN; Waterhouse DM; Hagan MK; Richards P; DeSilvio ML; Mahoney JM; Nagarwala Y
Breast Cancer Res Treat; 2013 Jan; 137(2):457-64. PubMed ID: 23224144
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
[TBL] [Abstract][Full Text] [Related]
9. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
[TBL] [Abstract][Full Text] [Related]
10. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
13. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
15. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
